CN1626077A - 神经退化性疾病的治疗 - Google Patents

神经退化性疾病的治疗 Download PDF

Info

Publication number
CN1626077A
CN1626077A CNA2004100573866A CN200410057386A CN1626077A CN 1626077 A CN1626077 A CN 1626077A CN A2004100573866 A CNA2004100573866 A CN A2004100573866A CN 200410057386 A CN200410057386 A CN 200410057386A CN 1626077 A CN1626077 A CN 1626077A
Authority
CN
China
Prior art keywords
purposes
phenyl
another
furyl
replacements
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004100573866A
Other languages
English (en)
Chinese (zh)
Inventor
符文美
刘鸿褀
卢大宇
邓哲明
郭盛助
李芳裕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carlsbad Technology Inc
Original Assignee
Carlsbad Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlsbad Technology Inc filed Critical Carlsbad Technology Inc
Publication of CN1626077A publication Critical patent/CN1626077A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004100573866A 2003-09-03 2004-08-26 神经退化性疾病的治疗 Pending CN1626077A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/653,859 US20040077702A1 (en) 2001-09-14 2003-09-03 Treatment of nuerodegenerative diseases
US10/653,859 2003-09-03

Publications (1)

Publication Number Publication Date
CN1626077A true CN1626077A (zh) 2005-06-15

Family

ID=34136658

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100573866A Pending CN1626077A (zh) 2003-09-03 2004-08-26 神经退化性疾病的治疗

Country Status (8)

Country Link
US (1) US20040077702A1 (https=)
EP (1) EP1512400B1 (https=)
JP (1) JP2005075834A (https=)
KR (1) KR20050024272A (https=)
CN (1) CN1626077A (https=)
AT (1) ATE460161T1 (https=)
DE (1) DE602004025885D1 (https=)
TW (1) TW200510329A (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
US20080200557A1 (en) * 2004-07-07 2008-08-21 Caritas St. Elizabeth Hospital Of Boston, Inc. Method for Inhibiting Lipid Peroxidation
US20080252028A1 (en) * 2007-04-16 2008-10-16 Ming-Tai Huang Shock absorbing device for toy stroller
WO2008136772A1 (en) * 2007-05-02 2008-11-13 Agency For Science, Technology And Research Method of monitoring retinopathy
US20140163082A1 (en) 2011-05-06 2014-06-12 King Khalid Eye Specialist Hospital Pyrazolyl compounds for use in reversing reactive gliosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US105149A (en) * 1870-07-05 Egbert l
US4355A (en) * 1846-01-15 Beehive
JP2928079B2 (ja) * 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US7115661B1 (en) * 1999-12-29 2006-10-03 Queen's University At Kingston Methods and compositions for mitigating pain
US5760230A (en) * 1996-10-11 1998-06-02 Bayer Aktiengesellschaft 4, 4'-bridged bis-2, 4-diaminoquinazolines
DE19642255A1 (de) * 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
GB9920566D0 (en) * 1999-08-31 1999-11-03 Univ London Screen for axon viability
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
DE60201921T2 (de) * 2001-01-24 2005-10-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Kondensierte Pyrazolverbindungen
CN1300116C (zh) * 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
US7049334B2 (en) * 2001-09-14 2006-05-23 Carlsbad Technology, Inc. Enhancement of learning and memory and treatment of amnesia
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
US20050089473A1 (en) * 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier

Also Published As

Publication number Publication date
DE602004025885D1 (de) 2010-04-22
US20040077702A1 (en) 2004-04-22
JP2005075834A (ja) 2005-03-24
TW200510329A (en) 2005-03-16
KR20050024272A (ko) 2005-03-10
EP1512400A1 (en) 2005-03-09
EP1512400B1 (en) 2010-03-10
ATE460161T1 (de) 2010-03-15

Similar Documents

Publication Publication Date Title
JP7140748B2 (ja) アミド化合物、その医薬組成物、及びその使用方法
IL255465A (en) Albocidiv drug enhancers with improved bioavailability
CN109069508A (zh) Ezh2抑制剂及其用途
CN1642542A (zh) 血管新生抑制剂
JP2018510849A (ja) ソベチロムの誘導体
DE102009051799B4 (de) Bifunktionale Prodrugs und Drugs
JP2011527704A (ja) 経口抗がん製剤
US8049038B2 (en) Carnitine conjugates of adamantanamines derivatives as dual prodrugs for various uses
EP4554929A1 (en) Preparation of stable psilocin salts, esters and conjugates and uses thereof
CN1742722A (zh) 抗血管生成的方法
JP6517833B2 (ja) 神経変性疾患の処置に有用なウィザノライド
CN1626077A (zh) 神经退化性疾病的治疗
US8080559B2 (en) 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin and its preparation and use for the treatment of cancer
EP4039679A1 (en) Novel compound and use thereof in treating autoimmune diseases
WO2025116822A1 (en) Near infrared fluorescence compounds and methods thereof
JP2025003966A (ja) キノンレダクターゼ２阻害剤化合物およびその使用
CA2460005C (en) Enhancement of learning and memory and treatment of amnesia with the use of fused pyrazoles
CN119233975A (zh) 新型化合物及其用于治疗自身免疫性疾病的用途
JP7382944B2 (ja) 神経変性疾患を予防・治療するための新規な化合物及びその応用
TW202128645A (zh) 喹諾酮羧酸衍生物
JP5794873B2 (ja) 抗腫瘍剤
CN103260614B (zh) 联合疗法
EP0042348A1 (fr) Dérivés de l'olivacine et leur application thérapeutique
CN1879619A (zh) 癌症治疗
CN1254241C (zh) 稠环吡唑化合物在制备增强学习和记忆及治疗遗忘症的药物中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050615